Michael Gelband’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Michael Gelband’s Portfolio GBT Stock Details GBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-26,472	Closed	-$846K	–	2487
2022 Q2	$846K	Buy	+26,472	New	+$775K	0.01%	1161
2021 Q4	–	Sell	-27,623	Closed	-$704K	–	2768
2021 Q3	$704K	Buy	+27,623	New	+$812K	0.01%	1203
2021 Q2	–	Sell	-11,571	Closed	-$472K	–	3001
2021 Q1	$472K	Buy	+11,571	New	+$532K	0.01%	1409
2020 Q4	–	Sell	-65,587	Closed	-$3.62M	–	2520
2020 Q3	$3.62M	Sell	65,587 -36,405	-36%	-$2.31M	0.07%	239
2020 Q2	$6.44M	Buy	101,992 +96,939	+1,918%	+$6.65M	0.17%	116
2020 Q1	$258K	Buy	+5,053	New	+$338K	0.01%	702
2019 Q3	–	Sell	-4,473	Closed	-$235K	–	1731
2019 Q2	$235K	Buy	+4,473	New	+$257K	0.01%	826

Other funds holding GBT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Michael Gelband's GBT Position: Q3 2022 in Review

Michael Gelband sold out of Global Blood Therapeutics, Inc. (GBT) in Q3 2022, closing a stake of 26,472 shares — an estimated $846K sold.

Michael Gelband first reported a position in GBT in Q2 2019 and held it in 7 quarters. The position peaked at $6.44M in Q2 2020. 247 funds tracked by Wall St. Rank hold GBT as of Q3 2022.

Michael Gelband reported no remaining Global Blood Therapeutics, Inc. position as of Q3 2022 after selling out during the quarter.
Michael Gelband sold 26,472 Global Blood Therapeutics, Inc. shares in Q3 2022, an estimated $846K.
Michael Gelband first reported a position in Global Blood Therapeutics, Inc. in Q2 2019 and held it in 7 quarters.
Michael Gelband's Global Blood Therapeutics, Inc. position peaked at $6.44M in Q2 2020.
247 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q3 2022.

Based on ExodusPoint Capital Management's 13F filing for Q3 2022, filed 10 Nov 2022.